UNSPSC 51162603: Benzonatate

This classification denotes an antitussive agent with the molecular formula C12H17NO2(C2H4O)n, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 5P4DHS6ENR, chemically known as 2,5,8,11,14,17,20,23,26-nonaoxaoctacosan-28-yl p-(butylamino)benzoate but more generally known as benzonatate, which bears US NIH Compound Identifier 7699. European Medicines Agency schedules Benzonatate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05760MIG.

UNSPSC 51162603 Benzonatate is a Commodity code that covers pharmaceutical products, but the recent state and local opportunities tagged under this code diverge significantly from benzonatate itself—a cough suppressant—and instead show procurement of naloxone, drug deactivation systems, and multi-source generic pharmaceuticals. State and local issuing bodies acquiring under this code include county health departments and cooperative purchasing alliances administering multi-jurisdictional pharmaceutical contracts. The scope reflects acquisition of emergency medical supplies and generic pharmaceutical inventories for distribution to public health facilities, emergency responders, and state and local government institutions rather than specialty or branded medications.

Recent activity shows two representative opportunities: Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, response due July 26, 2023; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 on January 20, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and over-the-counter products across participating state and local government facilities in Minnesota and Oregon, with responses due March 26, 2026, and contract awards effective July 1, 2026. The geographic spread includes Florida and the upper Midwest through cooperative purchasing vehicles. The MMCAP procurement requires vendors to supply through three authorized wholesalers, maintain current Good Manufacturing Practices certification and Drug Supply Chain Security Act compliance, hold professional liability insurance of $2,000,000, and accept a 3 percent administrative fee on all purchases.